Investment Thesis
Mustang Bio is a pre-revenue pharmaceutical company with zero sales, burning approximately $1M quarterly in operating losses. The balance sheet is heavily leveraged with $15.8M in long-term debt relative to only $8.6M in equity, creating significant financial constraint for a company still in development stages with an estimated 4-year cash runway at current burn rates.
Strengths
- Adequate cash position of $16.3M providing near-term operational runway
- Current ratio of 2.25x demonstrates short-term liquidity capacity
- Pre-revenue stage is typical for early-stage biotech with potential value if pipeline succeeds
Risks
- Zero revenue with no demonstrated commercial traction or market validation
- High leverage with 1.83x debt-to-equity ratio creates severe constraints if clinical trials fail or capital needs arise
- Persistent negative cash flow (-$1M operating cash burn) with limited financial flexibility to fund R&D or pivot strategy
- Negative interest coverage (-211.6x) indicates inability to service debt from operations; vulnerable to covenant violations or refinancing risk
- Estimated 4-year cash runway leaves minimal margin for pipeline setbacks, regulatory delays, or equity capital requirements
Key Metrics to Watch
- Operating cash flow trajectory and quarterly burn rate sustainability
- Clinical trial progress and FDA regulatory milestones for pipeline candidates
- Debt refinancing terms and covenant compliance given negative operating income
Financial Metrics
Revenue
0.0
Net Income
-955.0K
EPS (Diluted)
$-0.14
Free Cash Flow
-1.0M
Total Assets
16.6M
Cash
16.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-11.1%
ROA
-5.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.25x
Quick Ratio
2.25x
Debt/Equity
1.83x
Debt/Assets
48.2%
Interest Coverage
-211.60x
Long-term Debt
15.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:46:43.582767 |
Data as of: 2026-03-31 |
Powered by Claude AI